

New Test Announcement



Carbohydrate Antigen 19-9 (CA 19-9) testing to be performed at St. Luke's Laboratory.

Effective 11/20/2019, St. Luke's Laboratory will begin performing testing for Carbohydrate Antigen 19-9 (CA 19). Testing was previously performed at Mayo Clinic Laboratories. Turnaround times will be enhanced.

Serial monitoring of CA 19-9 is useful as an aid in monitoring disease status in those patients with confirmed pancreatic cancer who have levels of serum CA 19-9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort. CA 19-9 values must be interpreted in conjunction with all other clinical and laboratory data before a medical decision is determined.

Patients with prior CA 19-9 testing history will need to be re-baselined. When orders are placed in Expanse, the ordering provider will be prompted to answer a question regarding prior CA 19-9 testing history. If the ordering provider answers "YES", CA 19-9 testing will be performed in-house and at Mayo Clinic Laboratories. If the ordering provider answers "NO" only in-house testing will be performed. Re-baseline testing will be offered for a period of 6 months.

The reference range for CA 19-9 will remain the same.

St. Luke's Reference Range:

0.00 – 35.0 U/mL

If you have questions, please contact Kristin Baer, M.D. 218-249-5751, Chemistry Medical Director or Amber LaMourea, MT (ASCP) 218-249-5024, Immunology Technical Specialist.